PF-Atlas › Clinical Trials › NCT05779007

Dose Reduction and Discontinuation With Anti-Fibrotic Medications

Pirfenidone · Not specified

Registry ID
NCT05779007
Phase
Not specified
Status
Completed
Drug / intervention
Pirfenidone
Sponsor
Boehringer Ingelheim
Start
2023-04-18
Enrollment
2778
Locations
1

About this trial

The overarching aim of our study is to assess the incidence of dose reduction and discontinuations for pirfenidone and nintedanib.

View NCT05779007 on ClinicalTrials.gov →

Explore related

All Pirfenidone trialsAll IPF trials

Related trials

Pirfenidone — NCT00001959pirfenidone — NCT00662038Pirfenidone — NCT02951429Pirfenidone — NCT00287729Pirfenidone — NCT01504334Pirfenidone — NCT02932566
Medical disclaimer. This page summarizes public trial data for NCT05779007 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.